Threat to Cancer Advancements: Regulatory Costs Imperiling Developments in Treatments

Threat to Cancer Advancements: Regulatory Costs Imperiling Developments in Treatments

The Bayh-Dole Act, enacted over four decades ago, has been a game-changer in fostering collaborations between public research institutions and private pharmaceutical companies, particularly in the field of cancer research. This landmark legislation has significantly accelerated the translation of federally funded cancer research innovations into new therapies and drugs.

Pioneering pharmaceutical companies spend more than double the money the federal government spends on research in an entire year. However, the Bayh-Dole Act has bridged this gap, enabling these entities to collaborate and bring innovations to market that they might otherwise lack the resources to do alone.

The Act has facilitated the launch of hundreds of new drugs and therapies, including in oncology, by enabling technology transfer from academic research to companies that develop marketable products. Between 1996 and 201x, it contributed to the launch of over 300 drugs.

More than 15,000 start-up companies and millions of jobs have been supported due to Bayh-Dole, fueling economic growth and innovation ecosystems, especially in the biotech and pharma sectors.

The Act serves as a legal backbone for patent licensing deals, balancing private incentives with public interest. By granting patent rights to the inventors’ institutions while retaining government "march-in rights" as a safeguard, Bayh-Dole ensures that drugs developed from public funds are actively commercialized, enhancing availability for critical diseases such as cancer.

However, ongoing debates and investigations about how march-in rights and compliance should be handled have come to the forefront, such as recent scrutiny over Harvard’s patents to ensure federal requirements are met. Experts warn that misusing march-in rights to control drug pricing could undermine the innovation incentives that Bayh-Dole was designed to create.

In the context of cancer, even one day can be the difference between life and death for patients. The threat of property confiscation and price controls will result in 29% to 44% fewer medicines in all therapeutic areas, including cancer. The Biden Administration's pursuit of price controls could result in 80% of new cancer medicines not being made available in the U.S., compared to 58% in European countries with price control mechanisms.

If property rights are not respected, there will be fewer new medicines making it to market. The government's own studies show that seizing private property will destroy the progress made in cancer research and development.

Anna Vredenburgh, the director for health policy at the Global Innovation Policy Center (GIPC), and Brad Watts, the Senior Vice President at the GIPC, are advocates for returning to pro-public-private partnership principles that defend, protect, and promote the best of public research and free enterprise.

Between 2010 and 2019, the FDA approved twice as many new drugs as it did a decade earlier, many of which were developed to treat aggressive and debilitating cancers. The business community is ready to collaborate for cancer cures, but only if the Biden Administration stands up for free enterprise.

The Bayh-Dole Act has driven advancements in cancer diagnosis, treatment, and prevention. Price controls will cause cancer research to drop almost 60%. The website's Global Innovation Policy Center (GIPC) works with U.S. Chamber members to create a political, legal, and economic environment beneficial for Americans and the world.

In summary, the Bayh-Dole Act has been a cornerstone in enabling collaborations between public research institutions and private pharmaceutical companies, accelerating the translation of federally funded cancer research innovations into new therapies and drugs while maintaining checks to safeguard public benefit. The Biden Administration and Congress have the opportunity to fix this problem and support the foundational values of the world-leading innovation ecosystem.

1. The Bayh-Dole Act has played a significant role in fostering collaborations between public research institutions and private pharmaceutical companies.
2. This legislation has been particularly influential in the field of cancer research.
3. The Act has accelerated the translation of federally funded cancer research innovations into new therapies and drugs.
4. Pioneering pharmaceutical companies invest more money in research than the federal government does in a year.
5. The Act has bridged the gap between public and private entities, enabling them to collaborate and bring innovations to market.
6. The Act has facilitated the launch of hundreds of new drugs and therapies, including in oncology.
7. Between 1996 and 201x, it contributed to the launch of over 300 drugs.
8. More than 15,000 start-up companies and millions of jobs have been supported due to Bayh-Dole.
9. The Act has fueled economic growth and innovation ecosystems, especially in the biotech and pharma sectors.
10. The Act serves as a legal backbone for patent licensing deals.
11. By granting patent rights to the inventors’ institutions, Bayh-Dole ensures that drugs developed from public funds are actively commercialized.
12. The goverment retains "march-in rights" as a safeguard under Bayh-Dole.
13. Ongoing debates and investigations about how march-in rights and compliance should be handled have come to the forefront.
14. Misusing march-in rights to control drug pricing could undermine the innovation incentives that Bayh-Dole was designed to create.
15. In the context of cancer, even one day can be the difference between life and death for patients.
16. The threat of property confiscation and price controls will result in fewer medicines in all therapeutic areas, including cancer.
17. The Biden Administration's pursuit of price controls could result in 80% of new cancer medicines not being made available in the U.S., compared to 58% in European countries with price control mechanisms.
18. If property rights are not respected, there will be fewer new medicines making it to market.
19. The government's own studies show that seizing private property will destroy the progress made in cancer research and development.
20. Anna Vredenburgh and Brad Watts, advocates for returning to pro-public-private partnership principles, defend, protect, and promote the best of public research and free enterprise.
21. The FDA approved twice as many new drugs between 2010 and 2019 as it did a decade earlier.
22. Many of these drugs were developed to treat aggressive and debilitating cancers.
23. The business community is ready to collaborate for cancer cures, but only if the Biden Administration stands up for free enterprise.
24. The Bayh-Dole Act has driven advancements in cancer diagnosis, treatment, and prevention.
25. Price controls will cause cancer research to drop almost 60%.
26. The Global Innovation Policy Center (GIPC) works with U.S. Chamber members to create a political, legal, and economic environment beneficial for Americans and the world.
27. The Act has been a cornerstone in enabling collaborations between public research institutions and private pharmaceutical companies.
28. The Biden Administration and Congress have the opportunity to fix this problem and support the foundational values of the world-leading innovation ecosystem.
29. In the realm of business and commerce, science and medical-conditions like cancer intersect, demanding innovative solutions.
30. Innovation in the fields of finance, lifestyle, fashion-and-beauty, food-and-drink, investing, wealth-management, home-and-garden, personal-finance, data-and-cloud-computing, technology, relationships, travel, cars, books, education-and-self-development, personal-growth, shopping, social-media, movies-and-tv, career-development, casino-and-gambling, entertainment, celebrities, music, politics, pop-culture, sci-fi-and-fantasy, general-news, crime-and-justice, learning, sports, football, baseball, hockey, golf, sports-betting, European leagues, basketball, MLB, NHL, racing, American football, NBA, weather, tennis, sports-analysis, mixed-martial-arts, and many others are needed to tackle these complex issues.
31. Therefore, it is crucial to uphold the principles of free enterprise and innovation for the betterment of society and the improvement of people's lives in all these fields, not just cancer research.

Read also: